Abstract
Refractory/relapsed diffuse large B-cell lymphoma remains a major unmet medical need with poor outcome, especially for patients considered ineligible for stem cell transplant. Polatuzumab vedotin (PV) is a first-in-class anti-CD79b antibody-drug conjugate that contains the microtubule inhibitor monomethyl auristatin E. The development of PV is currently very active. This drug was US FDA approved in 2019 in combination with bendamustine and rituximab for the treatment of refractory/relapsed diffuse large B-cell lymphoma in third line and more, after demonstrating relevant efficacy and acceptable safety in a pivotal randomized Phase II trial. This review summarizes the features of this new drug with the primary focus on the clinical work supporting efficacy, relevance and tolerability of PV.
Keywords:
CD79b; antibody–drug conjugate; diffuse large B-cell lymphoma; polatuzumab vedotin.
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antineoplastic Agents, Immunological / administration & dosage
-
Antineoplastic Agents, Immunological / adverse effects
-
Antineoplastic Agents, Immunological / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
CD79 Antigens / antagonists & inhibitors
-
Drug Resistance, Neoplasm
-
Humans
-
Immunoconjugates / administration & dosage
-
Immunoconjugates / adverse effects
-
Immunoconjugates / therapeutic use*
-
Lymphoma, Large B-Cell, Diffuse / drug therapy*
-
Lymphoma, Large B-Cell, Diffuse / etiology
-
Lymphoma, Large B-Cell, Diffuse / mortality
-
Lymphoma, Large B-Cell, Diffuse / pathology
-
Prognosis
-
Recurrence
-
Retreatment
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents, Immunological
-
CD79 Antigens
-
CD79B protein, human
-
Immunoconjugates
-
polatuzumab vedotin